Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark Pharmaceuticals Ltd.

www.glenmarkpharma.com

Latest From Glenmark Pharmaceuticals Ltd.

Final Salvo? Galvus Infringement Case Simmers In India

Natco has sprung a challenge to Novartis’ vildagliptin patent in India, months before its expiry. The Indian firm will hold back further release of its product on the market amid legal action and it remains to be seen if Novartis will pursue damages.

India Intellectual Property

Glenmark Says Makeover To Be Finished By End 2019-20 As It Seeks To Spur Growth

Glenmark says its reorganization into three entities – one focused on generics and specialty drugs, the second on APIs and the third on new drug innovation – will be wrapped up by year-end as it seeks to accelerate sluggish earnings and reduce heavy debt.

Strategy Sales & Earnings

Asia Deal Watch: Astellas Looks To Vector Cell Tech From Japan’s RiKen In Oncology

RiKen gets $9.3m up front plus potential milestones and royalties for use of its aAVC technology, while retaining research rights to the platform. JW Pharmaceutical acquires Vietnam’s Euvipharm.

Deals Business Strategies

Glenmark Takes On Remogliflozin Infringers In India

Alleged infringers of the patent on remogliflozin are facing legal heat in India from Glenmark, in an ongoing case where copies of the product were apparently offered for sale including via third-party trading sites.

India Intellectual Property
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register